Member Info for OilMan1984

I sold out after the t/o RNS several weeks and have put a decent chunk into LBE! It’s a slow burner over there at present but hopefully not for much longer.

Good luck to all investors on the RRE board going forward. It’s without doubt been one of the most informative and polite BB’s on LSE. Feel sorry for investors that bought above £18.50 but unfortunately that’s life.

GLA with future investments.

Lago have now starting BUYING shares on the Naz! Something Brewing...............

https://clinicaltrials.gov/ct2/show/NCT04315948?term=discovery&recrs=a&draw=2

The treatment arm SOC + lopinavir / Ritonavir and lopinavir / ritonavir + interferon ß-1a has been ceased since June 29, 2020

The EU has bought 30,000 doses of the medicine for about 63 million euros from Gilead, and Finland is also getting medicine from this quota. The Ministry of Social Affairs and Health does not say how much medicine has been purchased.

“However, the remdesivirvir that prepares Gilead will not be the only remdesivir. Egypt and India, for example, will have production in the future. ”

The project will continue during the epidemic

The Solidarity research project will not end until the epidemic ends. If the drug is found to be useful, the research project will change so that all patients receive remdesivir.

“In the future, we will probably look at some receiving remdesivir and some in combination with remdesivir and interferon. The theoretical background is that it could help. Interferon activates natural killer defense cells, making it harder for viruses to multiply. ”

The text continues below
"I can't judge whether remdesivirir is more likely to help alone or in combination, but it makes sense to try both options in a randomized setting."

According to Tikkinen, there are, of course, other interesting drugs that are being considered by the WHO pharmacological team.

Tikkinen estimates that remdesivir will not be dramatically good or dramatically harmful in the treatment of coronavirus infection. The main disadvantage has been the increase in the liver values ??of the patients.

Solidarity is already well under way.

“In a few weeks, we may know if remdesivir is really useful or not. If it is useful, it will become standard treatment in those countries that can afford it and can buy it. ”

Coronary patients even younger
According to Tikkinen, patients who came to hospital during the second wave in Finland have been even younger, aged 20–40. The disease can be severe.

“They have pneumonia and need extra oxygen. They will be tested on Remdesivir for 10 days or until they get home; many of the young people have returned home in less than 10 days (even those who do not receive remdesiviir), ”says Tikkinen.

Remdesivir is expected to be useful in the pneumonia phase because it is thought to prevent the virus from multiplying in the body. If the patient is receiving intensive care, remdesivir is probably no longer helpful.

“Dexamethasone, an old and inexpensive cortisone, would instead seem to help those in intensive care; the benefit has been demonstrated in a reliable British Recovery study. The medicine helps in a situation where the body's inflammatory reaction goes so fast that it is life-threatening. ”

In previous studies, remdesivirvir accelerated healing
There are two important but too small studies of remdesivir. The first study, the results of which have been published in The Lancet , was conducted in Wuhan, China, and involved about 240 coronary patients. The drug did not reduce mortality from coronavirus disease.

“Those who received remdesivir improved in 21 days and those who received placebo in 23 days, but the difference is not statistically significant,” says Tikkinen.

The text continues below
Another study of remdesivirir was done in the United States, and it was estimated that the drug would speed recovery in about four days in those who improved, ”says Tikkinen.

The results of the study have been published in The New England Journal of Medicine .

After that, the United States reserved up to 90 percent of drug production in August-September.

The drug license came off quickly
After the study, the drug also quickly received marketing authorization, first in the United States and then in Europe.

“The European Commission, recommended by the (European Medicines Agency) EMA, I think too quickly granted a provisional marketing authorization for the medicine, based on this four-day acceleration of recovery that had been observed in only one study. This may have been due in part to the fact that Americans bought almost the entire stock of remdesivir - they had to give permission to get the drug to Europe as well. Non-medical reasons weigh a lot in today's medicine, ”says Tikkinen.

Seura Article:
Remdesivir is the most promising coronary drug so far and is being studied in Finland as well - The drug may accelerate the recovery of a coronary patient in hospital

According to experts, remdesivir is the most promising corona drug at the moment, but not a panacea. "The potential benefits will not be dramatically large," says Kari Tikkinen, the national lead researcher for the Solidarity project.
The medicine Remdesivir is currently in research use in coronary patients in some hospitals in Finland. Finland is participating in the Solidarity study coordinated by the World Health Organization, which tests various drugs and now especially the use of remdesivir in the treatment of coronavirus patients.

“Our goal is to prevent coronary patients who have been hospitalized with remdesivir come to treatment. The drug is administered intravenously once a day, ”says Professor Kari Tikkinen , Solidarity's national chief researcher .

According to Tikkinen, HUS, Oys, Tays and Kys are involved in the study. TYKS, on the other hand, is not involved. In addition to the university hospitals, six other hospitals are involved, such as Kanta-Häme Central Hospital and Satasaira Hospital in Pori.

The project previously found hydroxychloroquine, which Trump praises as a miracle drug, to be useless and even harmful in the treatment of coronavirus disease, so the drug has been dropped from the Solidarity study.

Only those who are willing will be drawn
Only adult coronavirus patients who are willing to be treated and who are being asked exactly what is involved can participate in the study of remdesivir. Internationally, about 8,000 patients are included in the study, and five patients have been recruited from Finland in the last two weeks.

Lue lisää
Patients are divided into two groups by random sampling (computer lottery): one receives standard care and the other, in addition to standard care, remdesivir. Both the patient and the doctors treating him know whether the patient is receiving remdesivir.

Solidarity is the only study in the world to investigate the suitability of remdesivir for the treatment of coronavirus infection. The American company Gilead Sciences, which makes the drug, does not give the drug in other randomized trials comparing it to standard care.

“The company sells the medicine for use, even though there is no complete certainty about the benefits,” says Tikkinen.

He finds this problematic, as medical treatment should always be based on reliable scientific evidence, not on commercial benefit or preliminary estimates. The drug costs thousands of euros per patient.

According to Tikkinen, there are three main questions in the Solidarity study: Does the drug prevent coronary deaths? Does it prevent you from getting into the power department? Does it have any serious side effects?

The text continues below
"These are all things that are relevant to the patient and for which there are no proper answer

@cwebb - link for the tweet?

@MaryMoo - Thanks for clearing that up!

@ ZumZum - The WHO website doesn’t reference the triple combination therapy being removed from the trial. If you remember i sent an email to the WHO and got a fairly prompt response confirming this.

Latest from WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

Sax - Maybe its a translation error! If T have been removed from trials then this would have been made public knowledge by now.

Good to see Marku has a sense of humour.......

''- Faro was founded in 2007. If we had American resources at our disposal during this time, we would be much further now. However, we once came to Finland from California because we did not want the children to become Americans, Jalkanen says''

Surely this should of been on an RNS.........

''If the WHO study is successful, Traumakine can get a marketing authorization quickly. It is currently known that the traumatic drug interferon-beta and the antiviral remdesivir are no longer included in the study. More information will come at any time.''

Markku Jalkanen
Job: Founder and CEO of the biopharmaceutical company Faron Pharmaceuticals.

Education: Doctor of Biochemistry, University of Turku 1982.

Other: The anticancer drug Clevegen is also in clinical trials. The company’s third drug, which is awaiting a patent and will also have an impact on the regulation of the human defense system, will also be announced this year.

THE development of medicine in Finland requires patience and determination, Jalkanen says.

- Medical research in Finland is of an exceptionally high standard. We also have a significant number of foundations supporting research, but no one builds drug development companies out of research. Finland does not believe that originator medicines could be developed here. It's a pity.

However, Jalkanen decided to establish his company in Finland, even though he and his wife, cancer researcher and academician Sirpa Jalkanen, have also had careers in the United States.

- Faro was founded in 2007. If we had American resources at our disposal during this time, we would be much further now. However, we once came to Finland from California because we did not want the children to become Americans, Jalkanen says.

The legs have three adult children and all work in the medical field.

- They have not been pushed into the industry, but everyone has also seen a lot of frustration and disappointments at home. Understanding often happens through mistakes, Jalkanen says.

THE BEST THING ABOUT DEVELOPMENT WORK, in addition to helping people, is that you get to work with smart and independent people.

- It is challenging to get them to work in the same direction, but when explaining to experts what is being done, they do not need to be motivated separately. It is very rewarding, Jalkanen says.

Jalkanen himself says that he has been really interested in human biology since he was young.

- Understanding the human regulatory system is so interesting that I could not think of anything else.

ALTHOUGH bringing Traumakine to market was, in a way, the biggest achievement of Jalkanen's career, he has no intention of slowing down even after that.

- compared to the leaders in US I'm young. It is a European matter to ask about retirement. Personally, I am not a person who would feel comfortable doing nothing, Jalkanen says.

The Turku-based biopharmaceutical company Turku has experienced exceptionally interesting times this year. The company’s ten-year-old drug, Traumakine, was selected in the spring as part of the World Health Organisation’s (WHO) SOLIDARY study, which looks for ways to improve the chances of survival for covid-19 patients. In addition, the drug is involved in two other studies.

Traumakine was originally developed to treat ARDS in lung disease. Although Traumakine has been at the top of the list of Faro's CEO Markku Jalkanen for years, the corona epidemic suddenly made the drug more topical than expected.

If the WHO study is successful, Traumakine can get a marketing authorization quickly. It is currently known that the traumatic drug interferon-beta and the antiviral remdesivir are no longer included in the study. More information will come at any time.

FOR Jalkanen, bringing the drug to market would be the culmination of a decade of work. In 2018, Traumakine had already entered the phase three research phase and the company was confident that it would work. However, in the study, Traumakine appeared ineffective. It was found that Traumakine was not effective in patients who were also being treated with corticosteroids such as cortisone at the same time. Now patients receiving cortisone have been considered separately in the study, and Jalkanen believes that evidence of the drug's effectiveness will soon be obtained.

- When Traumakine's development began, we had a couple of people involved. Now the company has 30 employees. I already know that I will offer champagnes to the whole group when the sales permit comes, Jalkanen says.

http://www.brainimmune.com/nih-first-randomized-controlled-trial-interferon-beta-1a-remdesivir-treating-covid-19/

https://www.the-scientist.com/news-opinion/seeking-an-early-covid-19-drug-researchers-look-to-interferons-67753

I wonder if the delay is due to a Takeover V Partner deal...... We have the patent protected!

This is surely worth a significant amount in the current climate. Any suggestions?

https://twitter.com/Covid19_DEI/status/1293927084776194048/photo/1

https://twitter.com/Covid19_DEI/status/1293927084776194048/photo/2

https://twitter.com/Covid19_DEI/status/1293927084776194048/photo/3

Munch - RRE IPO was at 50p and it managed to reach the lofty heights of ~£22.50!

If we only returned half them gains with LBE i’d be ecstatic! But like you say, patience is required here, so let’s not get to excited just yet!

GLA

https://www.youtube.com/watch?v=0l92Ndt6hg8&feature=youtu.be